{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', \"appropriate form and submit it to GSK within 24 hours of learning of the partner's\", 'pregnancy.', 'The female partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', \"24 hours of learning of a participant's pregnancy.\", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy for medical reasons will be', 'reported as an AE or SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study intervention by the investigator, will be reported to', 'GSK as described in Appendix 4. While the investigator is not obligated to actively', 'seek this information in former study participants, he or she may learn of an SAE', 'through spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue study', 'intervention.', '124']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', \"Genetic variation may impact a participant's response to therapy, susceptibility,\", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a 6-mL blood sample will be collected from participants who have consented', 'to participate for DNA analysis.', 'DNA samples will be used for research related to GSK2857916 or Multiple', 'Myeloma and related diseases. They may also be used to develop tests/assays', 'including diagnostic tests related to GSK2857916 or study treatments of this drug', 'class, and Multiple Myeloma. Genetic research may consist of the analysis of one or', 'more candidate genes or the analysis of genetic markers throughout the genome or', 'analysis of the entire genome (as appropriate).', 'DNA samples will be analyzed for described planned analyses. Additional analyses', 'will be conducted if it is hypothesized that this may help further understand the', 'clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to GSK2857916 or study treatments of this class. The', 'results of genetic analyses may be reported in the clinical study report or in a', 'separate study summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on GSK2857916 (or study treatments of', 'this class) or Multiple Myeloma continues but no longer than 15 years after the last', 'subject last visit or other period as per local requirements.', '125']['2017N330177_04', 'CONFIDENTIAL', '205678', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments and Study Treatment Rechallenge Guidelines', 'Phase I/II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology.', 'Liver Chemistry Stopping Criteria - Liver Stopping Event', 'ALT-absolute', 'ALT >5xULN', 'ALT Increase', 'ALT >3xULN persists for >4 weeks', 'Bilirubin1,2', 'ALT >3xULN and bilirubin >2xULN (>35% direct bilirubin)', 'INR\u00b2', 'ALT >3xULN and INR >1.5, if INR measured', 'Cannot Monitor', 'ALT >3xULN and cannot be monitored weekly for 4 weeks', 'Symptomatic\u00b3', 'ALT >3xULN associated with symptoms (new or worsening) believed to be related', 'to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments following ANY Liver Stopping Event', 'Actions', 'Follow Up Assessments', 'Report the event to GSK within 24 hours', 'Viral hepatitis serology4', 'Complete the liver event CRF and complete', 'Only in those with underlying chronic hepatitis B at', 'an SAE data collection tool if the event also', 'study entry (identified by positive hepatitis B', 'meets the criteria for an SAE\u00b2', 'surface antigen) quantitative hepatitis B DNA and', 'Perform liver event follow up assessments', 'hepatitis delta antibody5.', 'Monitor the participant until liver chemistries', 'Blood sample for pharmacokinetic (PK) analysis, if', 'resolve, stabilize, or return to within baseline', 'it can be obtained within 45 days after last dose', '(see MONITORING below)', 'Serum creatine phosphokinase (CPK) and lactate', 'Do not restart/rechallenge participant with', 'dehydrogenase (LDH).', 'study treatment unless allowed per protocol', 'Fractionate bilirubin, if total bilirubin>2xULN', 'and GSK Medical Governance approval is', 'granted (refer to language within this', 'Obtain complete blood count with differential to', 'Appendix)', 'assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or worsening of clinical', 'protocol or not granted, permanently', 'symptoms of liver injury, or hypersensitivity, on the', 'discontinue study treatment and may', 'AE report form', 'continue participant in the study for any', 'Record use of concomitant medications on the', 'protocol specified follow up assessments', 'concomitant medications report form including', 'MONITORING:', 'acetaminophen, herbal remedies, other over the', 'counter medications', 'For bilirubin or INR criteria:', 'Record alcohol use on the liver event alcohol', 'Repeat liver chemistries (include ALT, AST,', 'intake case report form', '126']\n\n###\n\n", "completion": "END"}